Publications

Select the publication year
Select an author  
  • A disease causing ATLASTIN 3 mutation affects multiple endoplasmic reticulum-related pathways.
    Behrendt L, Kurth I, Kaether C
    Cell Mol Life Sci 2019 (epub ahead of print)
  • Resting cells rely on the DNA helicase component MCM2 to build cilia.
    Casar Tena T, Maerz LD, Szafranski K, Groth M, Blätte TJ, Donow C, Matysik S, Walther P, Jeggo PA, Burkhalter MD, Philipp M
    Nucleic Acids Res 2019, 47(1), 134-51
  • Cohesin-mediated NF-κB signaling limits hematopoietic stem cell self-renewal in aging and inflammation.
    Chen Z, Amro EM, Becker F, Hölzer M, Rasa SMM, Njeru SN, Han B, Di Sanzo S, Chen Y, Tang D, Tao S, Haenold R, Groth M, Romanov VS, Kirkpatrick JM, Kraus JM, Kestler HA, Marz M, Ori A, Neri F, Morita Y, Rudolph KL
    J Exp Med 2019, 216(1), 152-75
  • Construction of cloning-friendly mini-genes for mammalian expression of full-length human NF1 isoforms.
    Cui Y, Morrison H
    Hum Mutat 2019, 40(2), 187-92
  • SilentMutations (SIM): a tool for analyzing long-range RNA-RNA interactions in viral genomes and structured RNAs.
    Desirò D, Hölzer M, Ibrahim B, Marz M
    Virus Res 2019, 260, 135-41
  • TFEB controls vascular development by regulating the proliferation of endothelial cells.
    Doronzo G, Astanina E, Corà D, Chiabotto G, Comunanza V, Noghero A, Neri F, Puliafito A, Primo L, Spampanato C, Settembre C, Ballabio A, Camussi G, Oliviero S, Bussolino F
    EMBO J 2019 (epub ahead of print)
  • It is not all about regeneration: planarians striking power to stand starvation.
    Felix DA, Gutiérrez-Gutiérrez Ó, Espada L, Thems A, González-Estévez C
    Semin Cell Dev Biol 2019 (epub ahead of print)
  • Conservation and divergence of the p53 gene regulatory network between mice and humans.
    Fischer M
    Oncogene 2019 (epub ahead of print)
  • Global importance of RNA secondary structures in protein coding sequences.
    Fricke M, Gerst R, Ibrahim B, Niepmann M, Marz M
    Bioinformatics 2019 (epub ahead of print)
  • Preclinical Assessment of MEK1/2 Inhibitors for Neurofibromatosis Type 2-Associated Schwannomas Reveal Differences in Efficacy and Drug Resistance Development.
    Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli A, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C
    Neuro-oncol 2019 (epub ahead of print)